title: Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion.
abstract: OBJECTIVE
  To establish a role for vascular endothelial growth factor (VEGF) during the onset and clinical course of neovascularization of the iris (NVI) in ischemic central retinal vein occlusion.
  
  
  METHODS
  Sixteen patients with ischemic central retinal vein occlusion were followed up for 12 months by clinical examination, retinal and iris angiography, and serial anterior chamber sampling of aqueous humor. Aqueous VEGF level was determined by enzyme-linked immunoassay, and permeability changes were estimated by capillary zone electrophoretic assessment of aqueous albumin.
  
  
  RESULTS
  A correlation was found between aqueous VEGF concentrations and the onset, persistence, and regression of NVI; extent of retinal capillary nonperfusion; and vascular permeability. The NVI occurred when aqueous VEGF concentrations were 849 to 1569 pg/mL and regressed fully when they fell below 550 pg/mL. Aqueous concentrations of serum albumin, a marker of increased permeability, correlated with increased VEGF. Placental growth factor was found at low levels only when VEGF levels exceeded 330 pg/mL. The NVI remained VEGF-dependent during the course of the disease, regressing only if VEGF concentrations were reduced after laser ablation of hypoxic retina.
  
  
  CONCLUSIONS
  The close temporal correlation between aqueous VEGF levels and the course of neovascularization and permeability in human ischemic central retinal vein occlusion indicates that increased aqueous VEGF level may predict the need for treatment, and that anti-VEGF therapy at an early stage of ischemic central retinal vein occlusion may be therapeutically beneficial.
authors.affiliation: Moorfields Eye Hospital, City Road, London EC1V 2PD, England.
authors.forename: Shelley R
authors.initials: SR
authors.lastname: Boyd
authors.forename: Ian
authors.initials: I
authors.lastname: Zachary
authors.forename: Usha
authors.initials: U
authors.lastname: Chakravarthy
authors.forename: George J
authors.initials: GJ
authors.lastname: Allen
authors.forename: G Brian
authors.initials: GB
authors.lastname: Wisdom
authors.forename: Ian A
authors.initials: IA
authors.lastname: Cree
authors.forename: John F
authors.initials: JF
authors.lastname: Martin
authors.forename: Philip G
authors.initials: PG
authors.lastname: Hykin
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001082:Aqueous Humor / Q000378:metabolism*; D002199:Capillary Permeability; D019075:Electrophoresis, Capillary; D016228:Endothelial Growth Factors / Q000378:metabolism*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism; D005451:Fluorescein Angiography; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000378:metabolism*; D007498:Iris / Q000098:blood supply*; D017075:Laser Coagulation; D008222:Lymphokines / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000209:etiology / Q000378:metabolism* / Q000601:surgery; D000072483:Placenta Growth Factor; D011257:Pregnancy Proteins / Q000378:metabolism; D012170:Retinal Vein Occlusion / Q000150:complications / Q000378:metabolism* / Q000601:surgery; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D016228:Endothelial Growth Factors; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; C000608036:PGF protein, human; D011257:Pregnancy Proteins; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D016222:Fibroblast Growth Factor 2; D000072483:Placenta Growth Factor